{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Squamous+Cell+Carcinoma+of+the+Head+and+Neck+Cancer&page=28",
    "query": {
      "condition": "Squamous Cell Carcinoma of the Head and Neck Cancer",
      "page": 28
    },
    "page_size": 10
  },
  "pagination": {
    "page": 28,
    "page_size": 10,
    "total_count": 1254,
    "total_pages": 126,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Squamous+Cell+Carcinoma+of+the+Head+and+Neck+Cancer&page=29&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Squamous+Cell+Carcinoma+of+the+Head+and+Neck+Cancer&page=27&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-16T06:52:53.750Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06084481",
      "title": "Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hepatocellular Carcinoma",
        "Pancreatic Ductal Adenocarcinoma",
        "Biliary Tract Cancers",
        "Esophageal Squamous Cell Carcinoma",
        "Triple Negative Breast Cancer",
        "Hormone Receptor+/Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer",
        "Head and Neck Squamous-Cell Carcinoma",
        "Platinum Resistant High Grade Epithelial Ovarian Cancer"
      ],
      "interventions": [
        {
          "name": "ABBV-400",
          "type": "DRUG"
        },
        {
          "name": "Itraconazole (ITZ)",
          "type": "DRUG"
        },
        {
          "name": "Bevacizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 325,
      "start_date": "2023-11-09",
      "completion_date": "2027-09",
      "has_results": false,
      "last_update_posted_date": "2026-10-14",
      "last_synced_at": "2026-10-16T06:52:53.750Z",
      "location_count": 20,
      "location_summary": "Duarte, California • San Francisco, California • Aurora, Colorado + 15 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Sarasota",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06084481"
    },
    {
      "nct_id": "NCT00002922",
      "title": "Paclitaxel in Treating Patients With Advanced Head and Neck Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Head and Neck Cancer"
      ],
      "interventions": [
        {
          "name": "paclitaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eastern Cooperative Oncology Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": null,
      "start_date": "1997-02-21",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2023-06-18",
      "last_synced_at": "2026-10-16T06:52:53.750Z",
      "location_count": 23,
      "location_summary": "Palo Alto, California • Stanford, California • Miami, Florida + 18 more",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00002922"
    },
    {
      "nct_id": "NCT00281866",
      "title": "Erlotinib in Treating Patients With Metastatic and/or Recurrent Head and Neck Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Head and Neck Cancer"
      ],
      "interventions": [
        {
          "name": "erlotinib hydrochloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 37,
      "start_date": "2005-07",
      "completion_date": "2007-03",
      "has_results": false,
      "last_update_posted_date": "2016-10-12",
      "last_synced_at": "2026-10-16T06:52:53.750Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00281866"
    },
    {
      "nct_id": "NCT01192815",
      "title": "Erlotinib Hydrochloride and Radiation Therapy in Stage III-IV Squamous Cell Cancer of the Head and Neck",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Stage III Squamous Cell Carcinoma of the Hypopharynx",
        "Stage III Squamous Cell Carcinoma of the Larynx",
        "Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity",
        "Stage III Squamous Cell Carcinoma of the Oropharynx",
        "Stage III Verrucous Carcinoma of the Larynx",
        "Stage III Verrucous Carcinoma of the Oral Cavity",
        "Stage IV Squamous Cell Carcinoma of the Hypopharynx",
        "Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity",
        "Stage IV Squamous Cell Carcinoma of the Nasopharynx",
        "Stage IV Squamous Cell Carcinoma of the Oropharynx",
        "Stage IV Verrucous Carcinoma of the Larynx",
        "Stage IV Verrucous Carcinoma of the Oral Cavity"
      ],
      "interventions": [
        {
          "name": "erlotinib hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "intensity-modulated radiation therapy",
          "type": "RADIATION"
        },
        {
          "name": "pharmacogenomic studies",
          "type": "OTHER"
        },
        {
          "name": "gene expression analysis",
          "type": "OTHER"
        },
        {
          "name": "3-dimensional conformal radiation therapy",
          "type": "RADIATION"
        },
        {
          "name": "biopsy",
          "type": "OTHER"
        },
        {
          "name": "pharmacological study",
          "type": "OTHER"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        },
        {
          "name": "questionnaire administration",
          "type": "OTHER"
        },
        {
          "name": "enzyme-linked immunosorbent assay",
          "type": "OTHER"
        },
        {
          "name": "polymorphism analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION",
        "OTHER"
      ],
      "sponsor": "Case Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 2,
      "start_date": "2011-01",
      "completion_date": "2012-10",
      "has_results": true,
      "last_update_posted_date": "2020-05-12",
      "last_synced_at": "2026-10-16T06:52:53.750Z",
      "location_count": 1,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01192815"
    },
    {
      "nct_id": "NCT03370276",
      "title": "Cetuximab & Nivolumab in Patients With Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Squamous Cell Carcinoma of the Oropharynx",
        "Squamous Cell Carcinoma of the Larynx",
        "Squamous Cell Carcinoma of the Oral Cavity",
        "Squamous Cell Carcinoma of the Hypopharynx",
        "Squamous Cell Carcinoma of the Paranasal Sinus",
        "Head and Neck Squamous Cell Carcinoma",
        "Squamous Cell Cancer",
        "Head and Neck Carcinoma"
      ],
      "interventions": [
        {
          "name": "Nivolumab",
          "type": "DRUG"
        },
        {
          "name": "Cetuximab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "H. Lee Moffitt Cancer Center and Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 95,
      "start_date": "2017-12-20",
      "completion_date": "2023-12-23",
      "has_results": true,
      "last_update_posted_date": "2026-04-02",
      "last_synced_at": "2026-10-16T06:52:53.750Z",
      "location_count": 3,
      "location_summary": "Tampa, Florida • Atlanta, Georgia • Columbus, Ohio",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03370276"
    },
    {
      "nct_id": "NCT02636036",
      "title": "Phase I Study of Enadenotucirev and PD-1 Inhibitor in Subjects With Metastatic or Advanced Epithelial Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Colorectal Cancer",
        "Squamous Cell Carcinoma of the Head and Neck",
        "Epithelial Tumor"
      ],
      "interventions": [
        {
          "name": "enadenotucirev",
          "type": "BIOLOGICAL"
        },
        {
          "name": "nivolumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Akamis Bio",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 51,
      "start_date": "2016-01-25",
      "completion_date": "2021-10-08",
      "has_results": false,
      "last_update_posted_date": "2021-11-09",
      "last_synced_at": "2026-10-16T06:52:53.750Z",
      "location_count": 6,
      "location_summary": "Tucson, Arizona • Duarte, California • Santa Monica, California + 3 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Lafayette",
          "state": "Indiana"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02636036"
    },
    {
      "nct_id": "NCT02949700",
      "title": "Phase I/II Study OF Metformin in Combination With Cisplatin and Radiation in Head and Neck Squamous Cell Carcinoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Head and Neck Squamous Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "Metformin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Baylor College of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 26,
      "start_date": "2017-01-26",
      "completion_date": "2022-07-07",
      "has_results": true,
      "last_update_posted_date": "2023-06-29",
      "last_synced_at": "2026-10-16T06:52:53.750Z",
      "location_count": 3,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02949700"
    },
    {
      "nct_id": "NCT01469429",
      "title": "Phase 1b Food Based Modulation of Biomarkers in Human Tissues at High-Risk for Oral Cancer.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma",
        "Salivary Gland Squamous Cell Carcinoma",
        "Stage 0 Hypopharyngeal Cancer",
        "Stage 0 Laryngeal Cancer",
        "Stage 0 Lip and Oral Cavity Cancer",
        "Stage 0 Nasopharyngeal Cancer",
        "Stage 0 Oropharyngeal Cancer",
        "Stage 0 Paranasal Sinus and Nasal Cavity Cancer",
        "Stage I Salivary Gland Cancer",
        "Stage I Squamous Cell Carcinoma of the Hypopharynx",
        "Stage I Squamous Cell Carcinoma of the Larynx",
        "Stage I Squamous Cell Carcinoma of the Lip and Oral Cavity",
        "Stage I Squamous Cell Carcinoma of the Nasopharynx",
        "Stage I Squamous Cell Carcinoma of the Oropharynx",
        "Stage I Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity",
        "Stage I Verrucous Carcinoma of the Larynx",
        "Stage I Verrucous Carcinoma of the Oral Cavity",
        "Stage II Salivary Gland Cancer",
        "Stage II Squamous Cell Carcinoma of the Hypopharynx",
        "Stage II Squamous Cell Carcinoma of the Larynx",
        "Stage II Squamous Cell Carcinoma of the Lip and Oral Cavity",
        "Stage II Squamous Cell Carcinoma of the Nasopharynx",
        "Stage II Squamous Cell Carcinoma of the Oropharynx",
        "Stage II Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity",
        "Stage II Verrucous Carcinoma of the Larynx",
        "Stage II Verrucous Carcinoma of the Oral Cavity",
        "Stage III Salivary Gland Cancer",
        "Stage III Squamous Cell Carcinoma of the Hypopharynx",
        "Stage III Squamous Cell Carcinoma of the Larynx",
        "Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity",
        "Stage III Squamous Cell Carcinoma of the Nasopharynx",
        "Stage III Squamous Cell Carcinoma of the Oropharynx",
        "Stage III Verrucous Carcinoma of the Larynx",
        "Stage III Verrucous Carcinoma of the Oral Cavity",
        "Stage IV Squamous Cell Carcinoma of the Hypopharynx",
        "Stage IV Squamous Cell Carcinoma of the Nasopharynx",
        "Stage IVA Salivary Gland Cancer",
        "Stage IVA Squamous Cell Carcinoma of the Larynx",
        "Stage IVA Oral Cavity Squamous Cell Carcinoma",
        "Stage IVA Squamous Cell Carcinoma of the Oropharynx",
        "Stage IVA Nasal Cavity and Paranasal Sinus Cancer",
        "Stage IVA Verrucous Carcinoma of the Larynx",
        "Stage IVA Verrucous Carcinoma of the Oral Cavity",
        "Stage IVB Salivary Gland Cancer",
        "Stage IVB Squamous Cell Carcinoma of the Larynx",
        "Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity",
        "Stage IVB Squamous Cell Carcinoma of the Oropharynx",
        "Stage IVB Oral Cavity Squamous Cell Carcinoma",
        "Stage IVB Verrucous Carcinoma of the Larynx",
        "Stage IVB Verrucous Carcinoma of the Oral Cavity",
        "Stage IVC Salivary Gland Cancer",
        "Stage IVC Squamous Cell Carcinoma of the Larynx",
        "Stage IVC Oral Cavity Squamous Cell Carcinoma",
        "Stage IVC Squamous Cell Carcinoma of the Oropharynx",
        "Paranasal Sinus and Nasal Cavity Squamous Cell Carcinoma",
        "Stage IVC Verrucous Carcinoma of the Larynx",
        "Stage IVC Verrucous Carcinoma of the Oral Cavity",
        "Tongue Cancer"
      ],
      "interventions": [
        {
          "name": "placebo",
          "type": "OTHER"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        },
        {
          "name": "questionnaire administration",
          "type": "OTHER"
        },
        {
          "name": "chemoprevention",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "Ohio State University Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "21 Years and older"
      },
      "enrollment_count": 70,
      "start_date": "2007-09-04",
      "completion_date": "2014-09-17",
      "has_results": false,
      "last_update_posted_date": "2020-02-20",
      "last_synced_at": "2026-10-16T06:52:53.750Z",
      "location_count": 1,
      "location_summary": "Columbus, Ohio",
      "locations": [
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01469429"
    },
    {
      "nct_id": "NCT03090412",
      "title": "Photodynamic Therapy With HPPH Compared to Standard of Care Surgery in Treating Patients With Oral Cavity Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Stage I Oral Cavity Squamous Cell Carcinoma",
        "Stage II Oral Cavity Squamous Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "HPPH",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Photodynamic Therapy",
          "type": "DRUG"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        },
        {
          "name": "Therapeutic Conventional Surgery",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER",
        "PROCEDURE"
      ],
      "sponsor": "Roswell Park Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2,
      "start_date": "2018-03-07",
      "completion_date": "2021-08-06",
      "has_results": true,
      "last_update_posted_date": "2022-06-02",
      "last_synced_at": "2026-10-16T06:52:53.750Z",
      "location_count": 2,
      "location_summary": "Buffalo, New York • Rochester, New York",
      "locations": [
        {
          "city": "Buffalo",
          "state": "New York"
        },
        {
          "city": "Rochester",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03090412"
    },
    {
      "nct_id": "NCT06366451",
      "title": "PBI-MST-01 (NCT04541108) Substudy AZN-05: Intratumoral Microdosing of Rilvegostomig, Volrustomig, Sabestomig, and AZD9592 in HNSCC",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Head and Neck Squamous Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "Rilvegostomig",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Volrustomig",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Sabestomig",
          "type": "BIOLOGICAL"
        },
        {
          "name": "AZD9592",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "AZD9592 + Rilvegostomig",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "AZD9592 + Volrustomig",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "AZD9592 + Sabestomig",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "AZD9592 + Pembrolizumab",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "Presage Biosciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 17,
      "start_date": "2024-05-22",
      "completion_date": "2026-03-25",
      "has_results": false,
      "last_update_posted_date": "2026-06-26",
      "last_synced_at": "2026-10-16T06:52:53.750Z",
      "location_count": 7,
      "location_summary": "Sacramento, California • The Bronx, New York • Chapel Hill, North Carolina + 3 more",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "The Bronx",
          "state": "New York"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06366451"
    }
  ]
}